Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 11/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HINT1 | P49773 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101375 | 0.87 | ADORA3 (0.53) | NT5EADORA3HPGDHINT1STING1 | |
| SCHEMBL31675122 | 0.87 | ADORA3 (0.47) | NT5EADORA3HPGDHINT1STING1 | |
| SCHEMBL29908542 | 0.86 | ADORA3 (0.52) | NT5EADORA3HPGDHINT1STING1 | |
| SCHEMBL12758342 | 0.85 | HINT1 (0.52) | NT5EADORA3HPGDHINT1STING1 | |
| SCHEMBL1374868 | 0.85 | HINT1 (0.52) | NT5EADORA3HPGDHINT1STING1 | |
| SCHEMBL3734057 | 0.85 | ADORA3 (0.51) | NT5EADORA3HPGDHINT1STING1 | |
| SCHEMBL12151803 | 0.85 | HINT1 (0.52) | NT5EADORA3HPGDHINT1STING1 | |
| SCHEMBL3427138 | 0.84 | ADORA3 (0.50) | NT5EADORA3HPGDHINT1STING1 | |
| SCHEMBL18490626 | 0.84 | ADORA3 (0.52) | NT5EADORA3HPGDHINT1STING1 | |
| SCHEMBL28911222 | 0.83 | HPGD (0.54) | NT5EADORA3HPGDHINT1STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | claimed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | UNIV CALIFORNIA (US) | 2021-10-28 | — | — | US | disclosed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | disclosed |
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | disclosed |
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | disclosed |
| US-7285658-B2 | Nucleotide mimics and their prodrugs | BIOTA, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| CN-1195768-C | 3' -substituted nucleoside derivatives | MATSUDA AKIRA (JP) | 2005-04-06 | — | — | CN | disclosed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | disclosed |
| EP-0747389-B1 | 3'-SUBSTITUTED NUCLEOSIDE DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-RE38090-E1 | Antitumor activity; useful for treatment and prevention of cancers | Matsuda, Akira (JP) | 2003-04-22 | — | — | US | disclosed |
| US-5763418-A | NUCLEOTIDE ANTITUMOR AGENTS | Matsuda, Akira (JP) | 1998-06-09 | — | — | US | disclosed |
| CN-1140453-A | 3' -substituted nucleoside derivatives | MATSUDA AKIRA (JP) | 1997-01-15 | — | — | CN | disclosed |
| EP-0747389-A1 | 3'-SUBSTITUTED NUCLEOSIDE DERIVATIVES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | NT5E 39/4885ADORA3 95/4885HPGD 1161/4885 |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | NT5E 154/4885ADORA3 729/4885HPGD 2801/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | NT5E 154/4885ADORA3 729/4885HPGD 2801/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | NT5E 154/4885ADORA3 729/4885HPGD 2801/4885 |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | NT5E 154/4885ADORA3 729/4885HPGD 2801/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | NT5E 39/4885ADORA3 95/4885HPGD 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.